- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01033617
IMPACT-CABG Trial: IMPlantation of Autologous CD133+ sTem Cells in Patients Undergoing CABG (IMPACT-CABG)
The IMPlantation of Autologous CD133+ sTem Cells in Patients Undergoing CABG With Left Ventricular Dysfunction: the IMPACT-CABG Study
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
CD133+ are well-characterized distinct early progenitor group of stem cells that possess high engraftment, pluripotent and angiogenic capacity and proved to be valuable for cardiac repair by promoting neovascularization, inhibition of apoptosis and cardiomyogenesis.
Our proposed research protocol involves patients with chronic ischemic heart disease and left ventricular dysfunction undergoing coronary artery bypass grafting (CABG). In this phase II clinical trial, prospective, randomized, 2 arm, double-blind, placebo-controlled study, we will assess the safety, feasibility and functional effect of intra-myocardial injection of highly selected autologous CD133+ bone marrow stem cells to placebo.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Quebec
-
Montreal, Quebec, Canada, H2W 1T8
- Centre de recherche du CHUM (CRCHUM)
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age ≥18 years, and ≤75 years.
- Patients with severe chronic ischemic cardiomyopathy manifested by Canadian Cardiovascular Society (CCS) class II or greater angina, and/or New York Heart Association (NYHA) class II or greater, AND who have undergone diagnostic coronary angiography demonstrating ≥70% diameter narrowing of at least 2 major coronary arteries or branches or ≥50% diameter narrowing of the left main coronary artery.
- A significant left ventricular systolic dysfunction evaluated by echocardiography or LV angiography (LV ejection fraction ≤45% but ≥25%) due to prior myocardial infarction. This area of left ventricular dysfunction should be akinetic or severely hypokinetic, not dyskinetic or aneurismal, when assessed by echocardiography or LV angiogram. This territory should be irrigated by one or a branch of the three major vascular territories (i.e. right coronary artery, left circumflex, or left anterior descending artery distribution) that will be bypassed during the surgical procedure.
- No contraindications or exclusions (see below).
- Willingness to participate and ability to provide informed consent.
Exclusion Criteria:
- Contraindications to magnetic resonance imaging including presence of an implantable cardiac defibrillator (ICD) or permanent pacemaker (PPM), or cases in which it is anticipated that an ICD or PPM will be implanted prior to the 6 month follow-up (thus precluding performance of follow-up MR scans), claustrophobia.
- Lack of ischemic symptoms (angina) prior to referral for CABG (i.e., patients with only 'silent' ischemia will be excluded).
- Need for urgent or emergent revascularization.
- Need for concomitant surgical procedure at the time of CABG (e.g. valve repair or replacement, aneurysm resection, etc.).
- Hemodynamically unstable patients, as defined by heart rate ≤40/min or ≥100/min, and/or systolic blood pressure <90 mmHg or ≥200 mmHg, and/or ongoing need for intravenous inotropic or vasopressor medications.
- Patients with confirmed myocardial infarction within 14 days, and/or rising cardiac biomarker proteins (i.e. troponin), and/or worsening ECG changes.
- Prior CABG surgery.
- Stroke within 3 months prior to planned CABG.
- Immunosuppressive medication (e.g. prednisone, cyclophosphamide, etanercept, etc.)
- Severe chronic renal insufficiency (serum creatinine ≥ 200 mmol/dl or need for dialysis), liver disease, (diagnosis of cirrhosis, chronic hepatitis, or elevation of serum transaminases ≥3 times the upper limit of normal), cerebrovascular disease requiring concomitant carotid endarterectomy, peripheral arterial disease (claudication as the primary factor limiting activity), active non-dermatological malignancy requiring on-going treatment, or any other condition that would place the patient at increased risk for complications in the judgment of the attending cardiologist or cardiac surgeon
- Contra-indication for bone marrow aspiration (Thrombocytopenia <50.000 mm3, INR >2.0, use of antiplatelet agents other than aspirin).
- Hemoglobin less than 10g/dL, white blood cell count less than 4,000/mm3, absolute neutrophil count less than 1500/mm3
- Active infection, with a temperature greater than 37.5°C within 48 hrs prior to surgery and an unexplained white blood cell count in excess of 10,000/mm3
- Myelodysplastic syndrome (MDS)
- Significant cognitive impairment
- Any condition associated with a life expectancy of less than 6 months
- Patients known allergic reaction or contraindication to any of the component of the CD133+ enriched cells
- Participation in other studies
- History of severe ventricular tachy-arrythmias
- Positive laboratory test results for syphilis, HIV, HBC, HCV, HTLV1 and HTLV2
- Pregnant woman
- Inability or unwillingness to provide written informed consent
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Placebo-vergelijker: Placebo
Saline solution with autologous plasma.
|
Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells,or placebo solution containing plasma and indistinguishable will be injected in the myocardium.
A total of 2.0 ml with 10-15 injections will be injected.
Andere namen:
|
Experimenteel: CD133+ stem cells
Autologous CD133+ intramyocardial injection at time of coronary artery bypass grafting.
|
Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells,or placebo solution containing plasma and indistinguishable will be injected in the myocardium.
A total of 2.0 ml with 10-15 injections will be injected.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Freedom from Major Adverse Cardiac Event: cardiac death, myocardial infarct, repeat coronary bypass grafting or percutaneous intervention of bypassed artery.
Tijdsspanne: 6 months
|
6 months
|
Freedom from major arrhythmia: sustained ventricular tachycardia or survived sudden death.
Tijdsspanne: 6 months
|
6 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Regional myocardial perfusion and function assessed by magnetic resonance scans.
Tijdsspanne: 6 months
|
6 months
|
Device performance end point: Feasibility to produce from 100ml of bone marrow aspiration a final cell product that contains a target CD133+ cells higher than 0.5 million with a purity superior to 30% and a recovery superior to 10%.
Tijdsspanne: Baseline
|
Baseline
|
On symptom severity and quality of life after CABG surgery.
Tijdsspanne: 6 months
|
6 months
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Nicolas Noiseux, MD, MSc, FRCSC, Montreal University
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- HD08.147
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Myocardinfarct
-
University Hospital, ToulouseInstitut National de la Santé Et de la Recherche Médicale, FranceWervingThalamisch infarctFrankrijk
-
Shanghai East HospitalWervingHerseninfarct | Herseninfarct | Infarct, middelste hersenslagader | Beroerte, ischemisch | Acute beroerte | Infarct, voorste hersenslagader | Infarct, PCA | Infarct, posterieure circulatie, hersenenChina
-
Maastricht University Medical CenterWerving
-
International Psychoanalytic University BerlinCharite University, Berlin, GermanyBeëindigdDroom stoornis | Trombotisch infarct | PCA-infarctDuitsland
-
Maastricht University Medical CenterVoltooidVentriculair septumdefect na een infarct | Hartruptuur na een infarct | Mitralis papillaire spierruptuur na infarctNederland
-
Centre Hospitalier Sud FrancilienVoltooidAcuut anterieur choroïdaal infarct (ACI) | Paramediaan Pontijns Infarct (IPP)Frankrijk
-
Deutsches Herzzentrum MuenchenVoltooidInfarct, myocardDuitsland
-
Mathieu ECHIVARDVoltooidInfarct, myocardFrankrijk
-
Beijing Suncadia Pharmaceuticals Co., LtdNog niet aan het wervenHersenzwelling, groot hemisferisch infarct